CAREER: A novel space-creation concept to enhance the survival and functionality of transplanted human stem cells

职业:一种新颖的空间创造概念,可增强移植的人类干细胞的存活率和功能

基本信息

  • 批准号:
    1346387
  • 负责人:
  • 金额:
    $ 20.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Standard Grant
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-15 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

CBET-0748129WenCell replacement therapy represents one of the most promising treatments for many diseases and injuries. Recent discovery of the in vitro protocols necessary to derive dopaminergic (DA) neurons in large quantities from both human embryonic stem cells and adult stem cells has made it possible to ultimately cure Parkinson's disease (PD). However, the efficacy of stem-cell transplantation has been significantly compromised by poor cell survival and functionality in vivo, due primarily to the formation of an inhibitory extracellular matrix (ECM)-rich scar tissue at the transplantation site as a result of host tissue inflammatory response associated with the transplantation procedure. This project is to develop clinically applicable cell replacement therapy for the treatment of neurodegenerative diseases. In this project, the Principal Investigator (PI) plans to achieve this goal by improving the survival and functionality of transplanted human adult stem cell-derived DA neurons in cell replacement therapy for PD based upon a novel space-creation concept.The results of this project will affect multiple scientific and technological communities, including tissue engineering, neuroscience, and developmental biology. Graduate, undergraduate, and high school students will be trained, motivated, and prepared for life-long careers in biomedical research by gaining experimental skills, technical and academic competencies, and readiness. Active involvement of students from diverse backgrounds, women, and underrepresented minority groups; presentation of research results in coursework; and their dissemination into the community through outreach activities will promote campus diversity and benefit society.
CBET-0748129 WenCell替代疗法是许多疾病和损伤最有前途的治疗方法之一。最近发现的在体外协议所需的衍生多巴胺能(DA)神经元在大量从人类胚胎干细胞和成人干细胞已经有可能最终治愈帕金森氏病(PD)。然而,干细胞移植的功效已被体内差的细胞存活和功能性显著损害,这主要是由于作为与移植程序相关的宿主组织炎症反应的结果,在移植部位形成富含抑制性细胞外基质(ECM)的瘢痕组织。本项目旨在开发临床适用的细胞替代疗法,用于治疗神经退行性疾病。本项目的主要研究者(PI)基于空间创造的新概念,计划通过改善移植的人成体干细胞衍生的DA神经元在PD细胞替代治疗中的存活和功能来实现这一目标,该项目的结果将影响组织工程学、神经科学和发育生物学等多个科学和技术领域。研究生,本科生和高中生将通过获得实验技能,技术和学术能力和准备,为生物医学研究的终身职业做好培训,激励和准备。来自不同背景的学生,妇女和代表性不足的少数群体的积极参与;在课程中介绍研究成果;并通过外展活动将其传播到社区,将促进校园的多样性和造福社会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xuejun Wen其他文献

Establishment of induced pluripotent stem cell line (ZZUi009-A) from an Alzheimer's disease patient carrying a PSEN1 gene mutation
从携带PSEN1基因突变的阿尔茨海默病患者中建立诱导多能干细胞系(ZZUi009-A)
  • DOI:
    10.1016/j.scr.2017.12.005
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    1.2
  • 作者:
    Yanlin Wang;Na Jing;Linlin Su;Changhe Shi;Pei Zhang;Zhilei Wang;Huifang Sun;Jing Yang;Yutao Liu;Xuejun Wen;Jin Zhang;Shoutao Zhang;Yuming Xu
  • 通讯作者:
    Yuming Xu
A novel radiolabeled TMTP1 for long-acting hepatocellular carcinoma therapeutics
一种用于长效肝细胞癌治疗的新型放射性标记 TMTP1
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    Lanlin Yao;Xuejun Wen;Wei Guo;Jianyang Fang;Xianzhong Zhang;Zhide Guo;Jinxiong Huang;Yesen Li
  • 通讯作者:
    Yesen Li
A paradigm of cancer immunotherapy based on 2-[18F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect
基于 2-[18F]FDG 和抗 PD-L1 mAb 组合增强抗肿瘤效果的癌症免疫治疗范例
  • DOI:
    10.1158/1078-0432.ccr-22-0159
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    11.5
  • 作者:
    Xuejun Wen;Changrong Shi;Xinying Zeng;Liang Zhao;Lanlin Yao;Zhida Liu;Lixia Feng;Deliang Zhang;Jinxiong Huang;Yesen Li;Qin Lin;Haojun Chen;Rongqiang Zhuang;Xiaoyuan Chen;Xianzhong Zhang;Zhide Guo
  • 通讯作者:
    Zhide Guo
Correction: CEPC Technical Design Report: Accelerator
  • DOI:
    10.1007/s41605-024-00501-9
  • 发表时间:
    2024-12-16
  • 期刊:
  • 影响因子:
    2.000
  • 作者:
    Waleed Abdallah;Tiago CarlosAdorno de Freitas;Konstantin Afanaciev;Shakeel Ahmad;Ijaz Ahmed;Xiaocong Ai;Abid Aleem;Wolfgang Altmannshofer;Fabio Alves;Weiming An;Rui An;Daniele Paolo Anderle;Stefan Antusch;Yasuo Arai;Andrej Arbuzov;Abdesslam Arhrib;Mustafa Ashry;Sha Bai;Yu Bai;Yang Bai;Vipul Bairathi;Csaba Balazs;Philip Bambade;Yong Ban;Triparno Bandyopadhyay;Shou-Shan Bao;Desmond P. Barber;Ays¸e Bat;Varvara Batozskaya;Subash Chandra Behera;Alexander Belyaev;Michele Bertucci;Xiao-Jun Bi;Yuanjie Bi;Tianjian Bian;Fabrizio Bianchi;Thomas Bieko¨tter;Michela Biglietti;Shalva Bilanishvili;Deng Binglin;Denis Bodrov;Anton Bogomyagkov;Serge Bondarenko;Stewart Boogert;Maarten Boonekamp;Marcello Borri;Angelo Bosotti;Vincent Boudry;Mohammed Boukidi;Igor Boyko;Ivanka Bozovic;Giuseppe Bozzi;Jean-Claude Brient;Anastasiia Budzinskaya;Masroor Bukhari;Vladimir Bytev;Giacomo Cacciapaglia;Hua Cai;Wenyong Cai;Wujun Cai;Yijian Cai;Yizhou Cai;Yuchen Cai;Haiying Cai;Huacheng Cai;Lorenzo Calibbi;Junsong Cang;Guofu Cao;Jianshe Cao;Antoine Chance;Xuejun Chang;Yue Chang;Zhe Chang;Xinyuan Chang;Wei Chao;Auttakit Chatrabhuti;Yimin Che;Yuzhi Che;Bin Chen;Danping Chen;Fuqing Chen;Fusan Chen;Gang Chen;Guoming Chen;Hua-Xing Chen;Huirun Chen;Jinhui Chen;Ji-Yuan Chen;Kai Chen;Mali Chen;Mingjun Chen;Mingshui Chen;Ning Chen;Shanhong Chen;Shanzhen Chen;Shao-Long Chen;Shaomin Chen;Shiqiang Chen;Tianlu Chen;Wei Chen;Xiang Chen;Xiaoyu Chen;Xin Chen;Xun Chen;Xurong Chen;Ye Chen;Ying Chen;Yukai Chen;Zelin Chen;Zilin Chen;Gang Chen;Boping Chen;Chunhui Chen;Hok Chuen Cheng;Huajie Cheng;Shan Cheng;Tongguang Cheng;Yunlong Chi;Pietro Chimenti;Wen Han Chiu;Guk Cho;Ming-Chung Chu;Xiaotong Chu;Ziliang Chu;Guglielmo Coloretti;Andreas Crivellin;Hanhua Cui;Xiaohao Cui;Zhaoyuan Cui;Brunella D’Anzi;Ling-Yun Dai;Xinchen Dai;Xuwen Dai;Antonio De Maria;Nicola De Filippis;Christophe De La Taille;Francesca De Mori;Chiara De Sio;Elisa Del Core;Shuangxue Deng;Wei-Tian Deng;Zhi Deng;Ziyan Deng;Bhupal Dev;Tang Dewen;Biagio Di Micco;Ran Ding;Siqin Ding;Yadong Ding;Haiyi Dong;Jianing Dong;Jing Dong;Lan Dong;Mingyi Dong;Xu Dong;Yipei Dong;Yubing Dong;Milos Dordevic;Marco Drewes;Mingxuan Du;Mingxuan Du;Qianqian Du;Xiaokang Du;Yanyan Du;Yong Du;Yunfei Du;Chun-Gui Duan;Zhe Duan;Yahor Dydyshka;Ulrik Egede;Walaa Elmetenawee;Yun Eo;Ka Yan Fan;Kuanjun Fan;Yunyun Fan;Bo Fang;Shuangshi Fang;Yuquan Fang;Ada Farilla;Riccardo Farinelli;Muhammad Farooq;Angeles Faus Golfe;Almaz Fazliakhmetov;Rujun Fei;Bo Feng;Chong Feng;Junhua Feng;Xu Feng;Zhuoran Feng;ZhuoranFeng;Luis Roberto Flores Castillo;Etienne Forest;Andrew Fowlie;Harald Fox;Hai-Bing Fu;Jinyu Fu;Benjamin Fuks;Yoshihiro Funakoshi;Emidio Gabrielli;Nan Gan;Li Gang;Jie Gao;Meisen Gao;Wenbin Gao;Wenchun Gao;Yu Gao;Yuanning Gao;Zhanxiang Gao;Yanyan Gao;Kun Ge;Shao-Feng Ge;Zhenwu Ge;Li-Sheng Geng;Qinglin Geng;Chao-Qiang Geng;Swagata Ghosh;Antonio Gioiosa;Leonid Gladilin;Ti Gong;Stefania Gori;Quanbu Gou;Sebastian Grinstein;Chenxi Gu;Gerardo Guillermo;Joao Guimaraes da Costa;Dizhou Guo;Fangyi Guo;Jiacheng Guo;Jun Guo;Lei Guo;Lei Guo;Xia Guo;Xin-Heng Guo;Xinyang Guo;Yun Guo;Yunqiang Guo;Yuping Guo;Zhi-Hui Guo;Alejandro Gutie´rrez-Rodríguez;Seungkyu Ha;Noman Habib;Jan Hajer;Francois Hammer;Chengcheng Han;Huayong Han;Jifeng Han;Liang Han;Liangliang Han;Ruixiong Han;Yang Han;Yezi Han;Yuanying Han;Tao Han;Jiankui Hao;Xiqing Hao;XiqingHao;Chuanqi He;Dayong He;Dongbing He;Guangyuan He;Hong-Jian He;Jibo He;Jun He;Longyan He;Xiang He;Xiao-Gang He;Zhenqiang He;Klaus Heinemann;Sven Heinemeyer;Yuekun Heng;María A. Herna´ndez-Ruíz;Jiamin Hong;Yuenkeung Hor;George W. S. Hou;Xiantao Hou;Xiaonan Hou;Zhilong Hou;Suen Hou;Caishi Hu;Chen Hu;Dake Hu;Haiming Hu;Jiagen Hu;Jun Hu;Kun Hu;Shouyang Hu;Yongcai Hu;Yu Hu;Zhen Hu;Zhehao Hua;Jianfei Hua;Chao-Shang Huang;Fa Peng Huang;Guangshun Huang;Jinshu Huang;Ke Huang;Liangsheng Huang;Shuhui Huang;Xingtao Huang;Xu-Guang Huang;Yanping Huang;Yonggang Huang;Yongsheng Huang;Zimiao Huang;Chen Huanyuan;Changgi Huh;Jiaqi Hui;Lihua Huo;Talab Hussain;Kyuyeong Hwang;Ara Ioannisian;Munawar Iqbal;Paul Jackson;Shahriyar Jafarzade;Haeun Jang;Seoyun Jang;Daheng Ji;Qingping Ji;Quan Ji;Xiaolu Ji;Jingguang Jia;Jinsheng Jia;Xuewei Jia;Zihang Jia;Cailian Jiang;Han Ren Jiang;Houbing Jiang;Jun Jiang;Xiaowei Jiang;Xin Jiang;Xuhui Jiang;Yongcheng Jiang;Zhongjian Jiang;Cheng Jiang;Ruiqi Jiao;Dapeng Jin;Shan Jin;Song Jin;Yi Jin;Junji Jis;Sunghoon Jung;Goran Kacarevic;Eric Kajfasz;Lidia Kalinovskaya;Aleksei Kampf;Wen Kang;Xian-Wei Kang;Xiaolin Kang;Biswajit Karmakar;Zhiyong Ke;Rijeesh Keloth;Alamgir Khan;Hamzeh Khanpour;Khanchai Khosonthongkee;KhanchaiKhosonthongkee;Bobae Kim;Dongwoon Kim;Mi Ran Kim;Minsuk Kim;Sungwon Kim;On Kim;Michael Klasen;Sanghyun Ko;Ivan Koop;Vitaliy Kornienko;Bryan Kortman;Gennady Kozlov;Shiqing Kuang;Mukesh Kumar;Chia Ming Kuo;Tsz Hong Kwok;Franc¸ois Sylvain Ren Lagarde;Pei-Zhu Lai;Imad Laktineh;Xiaofei Lan;Zuxiu Lan;Lia Lavezzi;Justin Lee;Junghyun Lee;Sehwook Lee;Ge Lei;Roy Lemmon;Yongxiang Leng;Sze Ching Leung;Hai Tao Li;Bingzhi Li;Bo Li;Bo Li;Changhong Li;Chao Li;Cheng Li;Cheng Li;Chunhua Li;Cui Li;Dazhang Li;Dikai Li;Fei Li;Gang Li;Gang Li;Gang Li;Gaosong Li;Haibo Li;Haifeng Li;Hai-Jun Li;Haotian Li;Hengne Li;Honglei Li;Huijing Li;Jialin Li;Jingyi Li;Jinmian Li;Jun Li;Leyi Li;Liang Li;Ling Li;Mei Li;Meng Li;Minxian Li;Pei-Rong Li;Qiang Li;Shaopeng Li;Shenghe Li;Shu Li;Shuo Li;Teng Li;Tiange Li;Tong Li;Weichang Li;Weidong Li;Wenjun Li;Xiaoling Li;Xiaomei Li;Xiaonan Li;Xiaoping Li;Xiaoting Li;Xin Li;Xinqiang Li;Xuekang Li;Yang Li;Yanwei Li;Yiming Li;Ying Li;Ying-Ying Li;Yonggang Li;Yonglin Li;Yufeng Li;Yuhui Li;Zhan Li;Zhao Li;Zhiji Li;Tong Li;Lingfeng Li;Fei Li;Jing Liang;Jinhan Liang;Zhijun Liang;Guangrui Liao;Hean Liao;Jiajun Liao;Libo Liao;Longzhou Liao;Yi Liao;Yipu Liao;Ayut Limphirat;AyutLimphirat;Tao Lin;Weiping Lin;Yufu Lin;Yugen Lin;Beijiang Liu;Bo Liu;Danning Liu;Dong Liu;Fu-Hu Liu;Hongbang Liu;Huangcheng Liu;Hui Liu;Huiling Liu;Jia Liu;Jia Liu;Jiaming Liu;Jianbei Liu;Jianyi Liu;Jingdong Liu;Jinhua Liu;Kai Liu;Kang Liu;Kun Liu;Mengyao Liu;Peng Liu;Pengcheng Liu;Qibin Liu;Shan Liu;Shidong Liu;Shuang Liu;Shubin Liu;Tao Liu;Tao Liu;Tong Liu;Wei Liu;Xiang Liu;Xiao-Hai Liu;Xiaohui Liu;Xiaoyu Liu;Xin Liu;Xinglin Liu;Xingquan Liu;Yang Liu;Yanlin Liu;Yao-Bei Liu;Yi Liu;Yiming Liu;Yong Liu;Yonglu Liu;Yu Liu;Yubin Liu;Yudong Liu;Yulong Liu;Zhaofeng Liu;Zhen Liu;Zhenchao Liu;Zhi Liu;Zhi-Feng Liu;Zhiqing Liu;Zhongfu Liu;Zuowei Liu;Mia Liu;Zhen Liu;Xiaoyang Liu;Xinchou Lou;Cai-Dian Lu;Jun-Xu Lu;Qiu Zhen Lu;Shang Lu;Shang Lu;Wenxi Lu;Xiaohan Lu;Yunpeng Lu;Zhiyong Lu;Xianguo Lu;Wei Lu;Bayarto Lubsandorzhiev;Sultim Lubsandorzhiev;Arslan Lukanov;Jinliang Luo;Tao Luo;xiaoan Luo;Xiaofeng Luo;Xiaolan Luo;Jindong Lv;Feng Lyu;Xiao-Rui Lyu;Kun-Feng Lyu;Ande Ma;Hong-Hao Ma;Jun-Li Ma;Kai Ma;Lishuang Ma;Na Ma;Renjie Ma;Weihu Ma;Xinpeng Ma;Yanling Ma;Yan-Qing Ma;Yongsheng Ma;Zhonghui Ma;Zhongjian Ma;Yang Ma;Mousam Maity;Lining Mao;Yanmin Mao;Yaxian Mao;Aure´lien Martens;Caccia Massimo Luigi Maria;Shigeki Matsumoto;Bruce Mellado;Davide Meloni;Lingling Men;Cai Meng;Lingxin Meng;Zhenghui Mi;Yuhui Miao;Mauro Migliorati;Lei Ming;Vasiliki A. Mitsou;Laura Monaco;Arthur Moraes;Karabo Mosala;Ahmad Moursy;Lichao Mu;Zhihui Mu;Nickolai Muchnoi;Daniel Muenstermann;Daniel Muenstermann;Pankaj Munbodh;William John Murray;Jérôme Nanni;Dmitry Nanzanov;Changshan Nie;Sergei Nikitin;Feipeng Ning;Guozhu Ning;Jia-Shu Niu;Juan-Juan Niu;Yan Niu;Edward Khomotso Nkadimeng;Kazuhito Ohmi;Katsunobu Oide;Hideki Okawa;Mohamed Ouchemhou;Qun Ouyang;Daniele Paesani;Carlo Pagani;Stathes Paganis;Collette Pakuza;Jiangyang Pan;Juntong Pan;Tong Pan;Xiang Pan;Papia Panda;Saraswati Pandey;Mila Pandurovic;Rocco Paparella;Roman Pasechnik;Emilie Passemar;Hua Pei;Xiaohua Peng;Xinye Peng;Yuemei Peng;Jialun Ping;Ronggang Ping;Souvik Priyam Adhya;Baohua Qi;Hang Qi;Huirong Qi;Ming Qi;Sen Qian;Zhuoni Qian;Congfeng Qiao;Guangyou Qin;Jiajia Qin;Laishun Qin;Liqing Qin;Qin Qin;Xiaoshuai Qin;Zhonghua Qin;Guofeng Qu;Antonio Racioppi;Michael Ramsey-Musolf;Shabbar Raza;Vladimir Rekovic;Jing Ren;Ju¨rgen Reuter;Tania Robens;Giancarlo Rossi;Manqi Ruan;Manqi Ruan;Leonid Rumyantsev;Min Sang Ryu;Renat Sadykov;Minjing Sang;Juan Jose´ Sanz-Cillero;Miroslav Saur;Nishil Savla;Michael A. Schmidt;Daniele Sertore;Ron Settles;Peng Sha;Ding-Yu Shao;Ligang Shao;Hua-Sheng Shao;Xin She;Chuang Shen;Hong-Fei Shen;Jian-Ming Shen;Peixun Shen;Qiuping Shen;Zhongtao Shen;Shuqi Sheng;Haoyu Shi;Hua Shi;Qi Shi;Shusu Shi;Xiaolei Shi;Xin Shi;Yukun Shi;Zhan Shi;Ian Shipsey;Gary Shiu;Chang Shu;Zong-Guo Si;Andrei Sidorenkov;Ivan Smiljanić;Aodong Song;Huayang Song;Jiaojiao Song;Jinxing Song;Siyuan Song;Weimin Song;Weizheng Song;Zhi Song;Shashwat Sourav;Paolo Spruzzola;Feng Su;Shengsen Su;Wei Su;Shufang Su;Yanfeng Sui;Zexuan Sui;Michael Sullivan;Baiyang Sun;Guoqiang Sun;Hao Sun;Hao-Kai Sun;Junfeng Sun;Liang Sun;Mengcheng Sun;Pengfei Sun;Sichun Sun;Xianjing Sun;Xiaohu Sun;Xilei Sun;Xingyang Sun;Xin-Yuan Sun;Yanjun Sun;Yongzhao Sun;Yue Sun;Zheng Sun;Zheng Sun;Narumon Suwonjandee;Elsayed Tag Eldin;Biao Tan;Bo Tang;Chuanxiang Tang;Gao Tang;Guangyi Tang;Jian Tang;Jingyu Tang;Liang Tang;Ying’Ao Tang;Junquan Tao;Abdel Nasser Tawfik;Geoffrey Taylor;Valery Telnov;Saike Tian;Riccardo Torre;Wladyslaw Henryk Trzaska;Dmitri Tsybychev;Yanjun Tu;Shengquan Tuo;Michael Tytgat;Ghalib Ul Islam;Nikita Ushakov;German Valencia;Jaap Velthuis;Alessandro Vicini;Trevor Vickey;Ivana Vidakovic;Henri Videau;Raymond Volkas;Dmitry Voronin;Natasa Vukasinovic;Xia Wan;Xuying Wan;Xiao Wang;Anqing Wang;Bin Wang;Chengtao Wang;Chuanye Wang;Ci Wang;Dayong Wang;Dou Wang;En Wang;Fei Wang;Fei Wang;Guanwen Wang;Guo-Li Wang;Haijing Wang;Haolin Wang;Jia Wang;Jian Wang;Jianchun Wang;Jianli Wang;Jiawei Wang;Jin Wang;Jin-Wei Wang;Joseph Wang;Kechen Wang;Lechun Wang;Lei Wang;Liguo Wang;Lijiao Wang;Lu Wang;Meng Wang;Na Wang;Pengcheng Wang;Qian Wang;Qun Wang;Shu Lin Wang;Shudong Wang;Taofeng Wang;Tianhong Wang;Tianyang Wang;Tong Wang;Wei Wang;Wei Wang;Xiaolong Wang;Xiaolong Wang;Xiaoning Wang;Xiao-Ping Wang;Xiongfei Wang;Xujian Wang;Yaping Wang;Yaqian Wang;Yi Wang;Yiao Wang;Yifang Wang;Yilun Wang;Yiwei Wang;You-Kai Wang;Yuanping Wang;Yuexin Wang;Yuhao Wang;Yu-Ming Wang;Yuting Wang;Zhen Wang;Zhigang Wang;Weiping Wang;Zeren Simon Wang;Biao Wang;Hui Wang;Lian-Tao Wang;Zihui Wang;Zirui Wang;Jia Wang;Tong Wang;Daihui Wei;Shujun Wei;Wei Wei;Xiaomin Wei;Yuanyuan Wei;Yingjie Wei;Liangjian Wen;Xuejun Wen;Yufeng Wen;Martin White;Peter Williams;Zef Wolffs;William John Womersley;Baona Wu;Bobing Wu;Guanjian Wu;Jinfei Wu;Lei Wu;Lina Wu;Linghui Wu;Minlin Wu;Peiwen Wu;Qi Wu;Qun Wu;Tianya Wu;Xiang Wu;Xiaohong Wu;Xing-Gang Wu;Xuehui Wu;Yaru Wu;Yongcheng Wu;Yuwen Wu;Zhi Wu;Xin Wu;Lei Xia;Ligang Xia;Shang Xia;Benhou Xiang;Dao Xiang;Zhiyu Xiang;Bo-Wen Xiao;Chu-Wen Xiao;Dong Xiao;Guangyan Xiao;Han Xiao;Meng Xiao;Ouzheng Xiao;Rui-Qing Xiao;Xiang Xiao;Yichen Xiao;Ying Xiao;Yu Xiao;Yunlong Xiao;Zhenjun Xiao;Hengyuan Xiao;Nian Xie;Yuehong Xie;Tianmu Xin;Ye Xing;Zhizhong Xing;Da Xu;Fang Xu;Fanrong Xu;Haisheng Xu;Haocheng Xu;Ji Xu;Miaofu Xu;Qingjin Xu;Qingnian Xu;Wei Xu;Wei Xu;Weixi Xu;Xinping Xu;Zhen Xu;Zijun Xu;Zehua Xu;Yaoyuan Xu;Feifei Xue;Baojun Yan;Bin Yan;Fen Yan;Fucheng Yan;Jiaming Yan;Liang Yan;Luping Yan;Qi-Shu Yan;Wenbiao Yan;Yupeng Yan;Luping Yan;Haoyue Yan;Dong Yang;Fengying Yang;Guicheng Yang;Haijun Yang;Jin Min Yang;Jing Yang;Lan Yang;Li Yang;Li Lin Yang;Lili Yang;Litao Yang;Mei Yang;Qiaoli Yang;Tiansen Yang;Xiaochen Yang;Yingjun Yang;Yueling Yang;Zhengyong Yang;Zhenwei Yang;Youhua Yang;Xiancong Yang;De-Liang Yao;Shi Yao;Lei Ye;Lingxi Ye;Mei Ye;Rui Ye;Rui Ye;Yecheng Ye;Vitaly Yermolchyk;Kai Yi;Li Yi;Yang Yi;Di Yin;Peng-Fei Yin;Shenghua Yin;Ze Yin;Zhongbao Yin;Zhang Yinhong;Hwi Dong Yoo;Zhengyun You;Charles Young;Boxiang Yu;Chenghui Yu;Fusheng Yu;Jie-Sheng Yu;Jinqing Yu;Lingda Yu;Zhao-Huan Yu;Felix Yu;Bingrong Yu;Changzheng Yuan;Li Yuan;Xing-Bo Yuan;Youjin Yuan;Junhui Yue;Qian Yue;Baobiao Yue;Un Nisa Zaib;Riccardo Zanzottera;Hao Zeng;Ming Zeng;Jian Zhai;Jiyuan Zhai;Xin Zhe Zhai;Xi-Jie Zhan;Ben-Wei Zhang;Bolun Zhang;Di Zhang;Guangyi Zhang;Hao Zhang;Hong-Hao Zhang;Huaqiao Zhang;Hui Zhang;Jialiang Zhang;Jianyu Zhang;Jianzhong Zhang;Jiehao Zhang;Jielei Zhang;Jingru Zhang;Jinxian Zhang;Junsong Zhang;Junxing Zhang;Lei Zhang;Lei Zhang;Liang Zhang;Licheng Zhang;Liming Zhang;Linhao Zhang;Luyan Zhang;Mengchao Zhang;Rao Zhang;Shulei Zhang;Wan Zhang;Wenchao Zhang;Xiangzhen Zhang;Xiaomei Zhang;Xiaoming Zhang;Xiaoxu Zhang;Xiaoyu Zhang;Xuantong Zhang;Xueyao Zhang;Yang Zhang;Yang Zhang;Yanxi Zhang;Yao Zhang;Ying Zhang;Yixiang Zhang;Yizhou Zhang;Yongchao Zhang;Yu Zhang;Yuan Zhang;Yujie Zhang;Yulei Zhang;Yumei Zhang;Yunlong Zhang;Zhandong Zhang;Zhaoru Zhang;Zhen-Hua Zhang;Zhenyu Zhang;Zhichao Zhang;Zhi-Qing Zhang;Zhuo Zhang;Zhiqing Zhang;Cong Zhang;Tianliang Zhang;Luyan Zhang;Guang Zhao;Hongyun Zhao;Jie Zhao;Jingxia Zhao;Jingyi Zhao;Ling Zhao;Luyang Zhao;Mei Zhao;Minggang Zhao;Mingrui Zhao;Qiang Zhao;Ruiguang Zhao;Tongxian Zhao;Yaliang Zhao;Ying Zhao;Yue Zhao;Zhiyu Zhao;Zhuo Zhao;Alexey Zhemchugov;Hongjuan Zheng;Jinchao Zheng;Liang Zheng;Ran Zheng;shanxi zheng;Xu-Chang Zheng;Wang Zhile;Weicai Zhong;Yi-Ming Zhong;Chen Zhou;Daicui Zhou;Jianxin Zhou;Jing Zhou;Jing Zhou;Ning Zhou;Qi-Dong Zhou;Shiyu Zhou;Shun Zhou;Sihong Zhou;Xiang Zhou;Xingyu Zhou;Yang Zhou;Yong Zhou;Yu-Feng Zhou;Zusheng Zhou;Demin Zhou;Dechong Zhu;Hongbo Zhu;Huaxing Zhu;Jingya Zhu;Kai Zhu;Pengxuan Zhu;Ruilin Zhu;Xianglei Zhu;Yingshun Zhu;Yongfeng Zhu;Xiao Zhuang;Xuai Zhuang;Mikhail Zobov;Zhanguo Zong;Cong Zou;Hongying Zou
  • 通讯作者:
    Hongying Zou
Radioiodinated 4-(p-Iodophenyl) Butanoic Acid-Modified Estradiol Derivative for ER Targeting SPECT Imaging
用于 ER 靶向 SPECT 成像的放射性碘化 4-(对碘苯基) 丁酸修饰雌二醇衍生物
  • DOI:
    10.1021/acs.analchem.1c03616
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    7.4
  • 作者:
    Duo Xu;Xiaoru Lin;Xinying Zeng;Xuejun Wen;Jingchao Li;Yesen Li;Jinxiong Huang;Xiaoyuan Chen;Zhide Guo;Xianzhong Zhang
  • 通讯作者:
    Xianzhong Zhang

Xuejun Wen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xuejun Wen', 18)}}的其他基金

CAREER: A novel space-creation concept to enhance the survival and functionality of transplanted human stem cells
职业:一种新颖的空间创造概念,可增强移植的人类干细胞的存活率和功能
  • 批准号:
    0748129
  • 财政年份:
    2008
  • 资助金额:
    $ 20.65万
  • 项目类别:
    Standard Grant

相似国自然基金

Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
  • 批准号:
    82070530
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
  • 批准号:
    32002421
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
  • 批准号:
    31902347
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

EAGER: Fertilizing the Tree of Life with novel taxa from deep-sea vent microbial metagenomes collected over time and space
EAGER:用随时间和空间收集的深海喷口微生物宏基因组中的新类群为生命之树施肥
  • 批准号:
    2409507
  • 财政年份:
    2024
  • 资助金额:
    $ 20.65万
  • 项目类别:
    Standard Grant
SBIR Phase I: Universal Crystal Growth Capsule and Novel Wafer Dicing Tool for In-Space Manufacturing
SBIR 第一阶段:用于太空制造的通用晶体生长舱和新型晶圆切割工具
  • 批准号:
    2419346
  • 财政年份:
    2024
  • 资助金额:
    $ 20.65万
  • 项目类别:
    Standard Grant
Multifunctional High Entropy Carbide and Boride (HECARBO) Ceramic Composites: Compositional Space, Novel Synthesis, and Property Tailoring
多功能高熵碳化物和硼化物 (HECARBO) 陶瓷复合材料:成分空间、新颖合成和性能定制
  • 批准号:
    EP/Y020804/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.65万
  • 项目类别:
    Research Grant
Customizable Artificial Intelligence for the Biomedical Masses: Development of a User-Friendly Automated Machine Learning Platform for Biology Image Analysis.
面向生物医学大众的可定制人工智能:开发用于生物图像分析的用户友好的自动化机器学习平台。
  • 批准号:
    10699828
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
High-performance deep neural networks for medical image analysis
用于医学图像分析的高性能深度神经网络
  • 批准号:
    10723553
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
Probing Amyloid Fibril Self-Assembly with Network Hamiltonian Simulations in Explicit Space
用显式空间中的网络哈密顿模拟探测淀粉样蛋白原纤维的自组装
  • 批准号:
    10715891
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
Charge-Based Brain Modeling Engine with Boundary Element Fast Multipole Method
采用边界元快速多极子法的基于电荷的脑建模引擎
  • 批准号:
    10735946
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
Defining single-channel paracellular (tight junction) conductances using nanotechnology
使用纳米技术定义单通道旁细胞(紧密连接)电导
  • 批准号:
    10593421
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
Predictive modeling of mammalian cell fate transitions over time and space with single-cell genomics
利用单细胞基因组学预测哺乳动物细胞命运随时间和空间转变的模型
  • 批准号:
    10572855
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
Changes in the Ionic Basis of GABAergic Inhibition that Contribute to Post-traumatic Epilepsy
导致创伤后癫痫的 GABA 能抑制离子基础的变化
  • 批准号:
    10713240
  • 财政年份:
    2023
  • 资助金额:
    $ 20.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了